Table 1.

Baseline clinical and laboratory characteristics of G170R homozygous PH1 patients who received kidney alone transplant and were followed post-transplant at Mayo^*

Patient	Age at symptom onset (yrs)	Pre-KTx Uox (mmol/24 hrs) off VB6	Age at PH diagnosis and start of pyridoxine therapy (yrs)	Age at ESRD (yrs)	Age at KTx (yrs)	Donor type	HLA mismatch	Induction immuno-suppression	Maintenance immuno-suppression
1	33	n/a	38	33	33/39	LURD	n/a	n/a	Tac/MMF/pred
2	23	1.71	33	32	33	DD	5	Alemtuzumab	Tac/MMF
3	6	1.36	67	67	67	LRD	2	Thymoglobulin	Tac/MMF/pred
4	12	2.27	12	33	33	LRD	0	n/a	MMF/pred/CSA→SRL
5	37	n/a	38	38	38	LRD	0	Basiliximab	Tac/MMF

^*Symptoms = nephrolithiasis or development of chronic kidney disease; normal Uox < 0.46 mmol/24 hrs; n/a = not available; LURD = living unrelated donor; DD = deceased donor; LRD = living related donor; Tac = tacrolimus; MMF = mycophenolate mofetil; Pred = prednisone; CSA = cyclosporine; SRL = sirolimus.